The renal (myo-)fibroblast: a heterogeneous group of cells
- PMID: 22851626
- DOI: 10.1093/ndt/gfs296
The renal (myo-)fibroblast: a heterogeneous group of cells
Abstract
Several studies have demonstrated that mesenchymal stem cells have the capacity to reverse acute and chronic kidney injury in different experimental models by paracrine mechanisms. This paracrine action may be accounted for, at least in part, by microvesicles (MVs) released from mesenchymal stem cells, resulting in a horizontal transfer of mRNA, microRNA and proteins. MVs, released as exosomes from the endosomal compartment, or as shedding vesicles from the cell surface, are now recognized as being an integral component of the intercellular microenvironment. By acting as vehicles for information transfer, MVs play a pivotal role in cell-to-cell communication. This exchange of information between the injured cells and stem cells has the potential to be bi-directional. Thus, MVs may either transfer transcripts from injured cells to stem cells, resulting in reprogramming of their phenotype to acquire specific features of the tissue, or conversely, transcripts could be transferred from stem cells to injured cells, restraining tissue injury and inducing cell cycle re-entry of resident cells, leading to tissue self-repair. Upon administration with a therapeutic regimen, MVs mimic the effect of mesenchymal stem cells in various experimental models by inhibiting apoptosis and stimulating cell proliferation. In this review, we discuss whether MVs released from mesenchymal stem cells have the potential to be exploited in novel therapeutic approaches in regenerative medicine to repair damaged tissues, as an alternative to stem cell-based therapy.
Similar articles
-
Therapeutic potential of mesenchymal stem cell-derived microvesicles.Nephrol Dial Transplant. 2012 Aug;27(8):3037-42. doi: 10.1093/ndt/gfs168. Nephrol Dial Transplant. 2012. PMID: 22851627 Review.
-
Role of stem-cell-derived microvesicles in the paracrine action of stem cells.Biochem Soc Trans. 2013 Feb 1;41(1):283-7. doi: 10.1042/BST20120192. Biochem Soc Trans. 2013. PMID: 23356298 Review.
-
Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury.Nephrol Dial Transplant. 2011 May;26(5):1474-83. doi: 10.1093/ndt/gfr015. Epub 2011 Feb 15. Nephrol Dial Transplant. 2011. PMID: 21324974
-
Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information.Curr Opin Nephrol Hypertens. 2010 Jan;19(1):7-12. doi: 10.1097/MNH.0b013e328332fb6f. Curr Opin Nephrol Hypertens. 2010. PMID: 19823086 Review.
-
MicroRNAs and mesenchymal stem cells.Vitam Horm. 2011;87:291-320. doi: 10.1016/B978-0-12-386015-6.00033-0. Vitam Horm. 2011. PMID: 22127248 Review.
Cited by
-
ZEB2 controls kidney stromal progenitor differentiation and inhibits abnormal myofibroblast expansion and kidney fibrosis.JCI Insight. 2023 Jan 10;8(1):e158418. doi: 10.1172/jci.insight.158418. JCI Insight. 2023. PMID: 36445780 Free PMC article.
-
The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury.Biology (Basel). 2022 Oct 28;11(11):1589. doi: 10.3390/biology11111589. Biology (Basel). 2022. PMID: 36358290 Free PMC article. Review.
-
Short histological kaleidoscope - recent findings in histology. Part I.Rom J Morphol Embryol. 2022 Jan-Mar;63(1):7-29. doi: 10.47162/RJME.63.1.01. Rom J Morphol Embryol. 2022. PMID: 36074664 Free PMC article. Review.
-
Signaling pathways of chronic kidney diseases, implications for therapeutics.Signal Transduct Target Ther. 2022 Jun 9;7(1):182. doi: 10.1038/s41392-022-01036-5. Signal Transduct Target Ther. 2022. PMID: 35680856 Free PMC article. Review.
-
Janus-Faced: Molecular Mechanisms and Versatile Nature of Renal Fibrosis.Kidney360. 2020 May 15;1(7):697-704. doi: 10.34067/KID.0001972020. eCollection 2020 Jul 30. Kidney360. 2020. PMID: 35372942 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources